Vaxxinity Inc stock (US92239B1035): Trading at historic low amid biotech challenges

Vaxxinity Inc (OTCM:VAXX) shares are trading at $0.0001 with a market cap under $20K, reflecting significant challenges in the biotech sector for US investors.

Vaxxinity Inc, a clinical-stage biotech firm, has seen its stock price drop to $0.0001 on the OTC market as of recent trading data. The company, listed under OTCM:VAXX, now holds a market capitalization of approximately $19K, highlighting the volatility in small-cap biotechs. This extreme low raises questions for retail investors tracking US-listed names in immunotherapy and neurology.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Vaxxinity Inc
• Sector/industry: Biotechnology
• Headquarters/country: USA
• Core markets: US and global
• Key revenue drivers: Clinical trials, partnerships
• Home exchange/listing venue: OTC Markets (VAXX)
• Trading currency: USD

Vaxxinity Inc: core business model

Vaxxinity Inc develops synthetic peptide immunotherapy platforms targeting diseases like chronic inflammation, oncology, and neurodegeneration. The company's approach uses proprietary technology to create targeted immune responses without traditional vaccines. This model aims to address unmet needs in areas such as Alzheimer's and cancer, positioning it within the innovative biotech space relevant to US investors.

Founded to leverage peptide tech, Vaxxinity has focused on clinical advancement since its public listing. The firm operates primarily in the US, with trials conducted under FDA oversight, making it a watchpoint for investors interested in domestic biotech pipelines.

Main revenue and product drivers for Vaxxinity Inc

Vaxxinity's pipeline includes candidates like VXX-301 for oncology and VXX-401 for neurodegeneration. Revenue potential stems from milestone payments, partnerships, and eventual commercialization if trials succeed. As a pre-revenue biotech, funding through equity raises and grants supports R&D, a common model in the sector.

The stock traded at $0.00010 USD on OTC Markets recently, according to GuruFocus as of recent data. This level reflects dilution and market sentiment challenges typical for micro-cap biotechs.

Vaxxinity Inc matters for US investors

As an OTC-listed biotech with US headquarters, Vaxxinity offers exposure to cutting-edge immunotherapy research amid a robust domestic pharma market. US investors benefit from familiarity with FDA processes and potential for sector-wide catalysts like trial data.

Conclusion

Vaxxinity Inc remains a high-risk, micro-cap biotech with a peptide platform targeting major diseases. Current trading levels underscore execution risks and funding needs common in early-stage firms. US investors should monitor pipeline updates and capital raises for potential shifts.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.